TVTX
Travere Therapeutics Inc
52.00$
-2.6%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 3.5% | 36.4% | 3.6% | 22.9% | 2.6% | 3.4% | 5.7% | 1.3% | 1.0% | 2.0% | 21.0% | 1.3% | 5.6% | |
| 96.5% | 63.6% | 96.4% | 77.1% | 97.4% | 96.6% | 94.3% | 98.7% | 99.0% | 98.0% | 79.0% | 98.7% | 94.4% | |
| 163.3% | 130.4% | 277.0% | 100.4% | 82.2% | 83.0% | 57.4% | 43.1% | 31.5% | 44.6% | 44.9% | 35.5% | 38.4% | |
| 182.8% | 141.1% | 155.2% | 119.7% | 104.3% | 92.9% | 89.1% | 66.6% | 52.4% | 78.4% | 63.1% | 56.7% | 61.6% | |
| 346.1% | 247.4% | 432.9% | 201.0% | 186.7% | 177.8% | 146.5% | 109.7% | 83.9% | 123.0% | 108.0% | 96.4% | 101.2% | |
| -249.6% | -183.8% | -336.5% | -123.9% | -89.3% | -81.2% | -52.2% | -11.1% | 15.1% | -25.0% | -29.0% | 2.3% | -6.8% | |
| 7.6% | 6.3% | 6.8% | 5.2% | 4.4% | 3.8% | 3.5% | 2.5% | 1.7% | 1.8% | 1.8% | 1.3% | 1.6% | |
| -240.5% | -196.5% | -328.1% | -128.6% | -87.2% | -80.7% | -50.4% | -11.1% | 15.6% | -16.2% | -28.9% | -20.6% | -11.3% | |
| 0.0% | 0.2% | 0.5% | 0.2% | -0.1% | -0.1% | 0.0% | 0.0% | 0.0% | 0.7% | -0.1% | -0.1% | 0.1% | |
| 406.3% | -200.1% | -328.9% | -130.1% | -87.1% | -80.6% | -50.4% | -11.1% | 15.6% | 2.1% | -29.2% | -20.5% | -7.4% | |
| -202.0% | -163.9% | -297.5% | -104.3% | -64.9% | -60.7% | -31.2% | 3.6% | 26.8% | -0.5% | -7.2% | -16.9% | 1.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.